Programs and Projects

Prostate Cancer Clinical Trials - University of Arizona (Multicenter Sites)

Agent: Selenium yeast
Contact: Frederick Ahmann, M.D.
DCP Program Director: Howard Parnes, M.D.

The purpose of this study is to see if selenium in the form of a high-selenium yeast tablet taken daily can slow the progression of localized prostate cancer (Gleason score ≤ 7) in men who have chosen "watchful waiting" rather than surgery or radiation therapy. Patients will receive this medication for different periods of time depending upon test results. The study is being conducted under the auspices of the University Arizona at Tucson. This study is now closed to accrual.

[This is a phase 2 randomized double-blind placebo controlled phase chemoprevention trial of selenized yeast in men managed by watchful waiting with early prostate cancer. The primary endpoint (s) are PSA velocity and change in management for clinical progression.]